Holen Sie sich die Stockscreener-App
4.78
0.63%
0.03
Handel nachbörslich:
4.78
Schlusskurs vom Vortag:
$4.75
Offen:
$4.81
24-Stunden-Volumen:
997.14K
Relative Volume:
0.57
Marktkapitalisierung:
$667.59M
Einnahmen:
$7.83M
Nettoeinkommen (Verlust:
$-64.92M
KGV:
-9.024
EPS:
-0.5297
Netto-Cashflow:
$-47.22M
1W Leistung:
+6.94%
1M Leistung:
+25.79%
6M Leistung:
+110.57%
1J Leistung:
+273.44%
1-Tages-Spanne:
$4.695
$4.875
1-Wochen-Bereich:
$4.215
$4.88
52-Wochen-Spanne:
$1.16
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
4.78 | 663.40M | 7.83M | -64.92M | -47.22M | -0.5297 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-16 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-05-28 | Eingeleitet | Wedbush | Outperform |
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Guggenheim initiates coverage of Aclaris Therapeutics (ACRS) with buy recommendation - MSN
MSN Money - MSN
Aclaris (ACRS) CMO vesting 36,375 RSUs with 9,330 shares tax withheld - Stock Titan
Aclaris Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Aclaris Reports Phase 1a Results for ATI-052, Advances Pipeline - MyChesCo
Aclaris Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth - Yahoo Finance
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody CandidatesSlideshow (NASDAQ:ACRS) 2026-04-28 - Seeking Alpha
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus - MarketBeat
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4R? Bispecific Antibody, and Announces Lichen Planus as Lead Indication f - Investing News Network
Aclaris Posts Strong Phase 1a ATI-052 Data, Sets Lichen Planus As Lead Indication For ATI-2138 - RTTNews
Aclaris Therapeutics says positive full top line results from Phase 1a clinical trial of ATI-055 - marketscreener.com
Aclaris Reports Positive ATI-052 Phase 1a Trial Results - TipRanks
Aclaris reports phase 1a trial results for ATI-052 antibody - Investing.com
Aclaris reports phase 1a trial results for ATI-052 antibody By Investing.com - Investing.com Canada
Aclaris Therapeutics announced that the Phase 1B clinical trial of its drug candidate ATI-052 is currently actively recruiting patients. - Bitget
Aclaris (NASDAQ: ACRS) touts ATI-052 data, targets lichen planus with ATI-2138 - Stock Titan
Aclaris Therapeutics Announces Positive Full Top Line - GlobeNewswire
Aclaris Therapeutics Insider Sold Shares Worth $1,359,000, According to a Recent SEC Filing - marketscreener.com
Aclaris targets lichen planus, a disease with no approved therapies - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Major Shareholder Braden Michael Leonard Sells 300,000 Shares - MarketBeat
Leonard Braden Michael sells $1.36m in Aclaris Therapeutics stock By Investing.com - Investing.com South Africa
Leonard Braden Michael sells $1.36m in Aclaris Therapeutics stock - Investing.com
Aclaris Therapeutics (NASDAQ: ACRS) insider-linked fund sells 300,000 shares - Stock Titan
BML Investment lists 13.95M shares (9.9%) in Aclaris (NASDAQ: ACRS) - Stock Titan
Aclaris to release ATI-052 trial data, ATI-2138 update Tuesday - Investing.com
Aclaris to release ATI-052 trial data, ATI-2138 update Tuesday By Investing.com - Investing.com Canada
What Aclaris will reveal Tuesday on two immune-disease drug programs - Stock Titan
Aclaris Therapeutics to Announce Phase 1a Trial Results for ATI-052 and Lead Indication Selection for ATI-2138 on April 28, 2026 - Quiver Quantitative
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 - GlobeNewswire
Aclaris Therapeutics (ACRS) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr
Aclaris Therapeutics (ACRS) Proxy filing Summary - Quartr
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap DownHere's What Happened - MarketBeat
Aclaris Therapeutics, Inc. ($ACRS) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Aclaris Therapeutics, Inc. SEC Filing - Stock Titan
Executive pay, board elections in Aclaris Therapeutics (NASDAQ: ACRS) 2026 proxy - Stock Titan
Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 - MSN
Aclaris (ACRS) Stock Gap Down Watch (Investor Interest) 2026-04-20Stock Analysis Community - Cổng thông tin điện tử tỉnh Tây Ninh
Oppenheimer Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10 - Moomoo
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Oppenheimer initiates coverage of Aclaris Therapeutics (ACRS) with outperform recommendation - MSN
ACRS Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target - Moomoo
Oppenheimer initiates Aclaris stock with Outperform rating By Investing.com - Investing.com Australia
Oppenheimer initiates Aclaris stock with Outperform rating - Investing.com
H.C. Wainwright reiterates Aclaris stock rating on drug trial data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Aclaris stock rating on drug trial data - Investing.com
Aclaris (ACRS) Stock: Momentum Shift (Marginal Gain) 2026-04-15Fast Rising Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):